Treatment with tocilizumab and other bDMARDs in patients with cid+AA or idio+AA
| TOC | Other bDMARDs | P value | |
| Patients, n (%) | 34 | 25 | |
| Female gender, n (%) | 33 (95.6) | 10 (40.0) | 0.00001 |
| Age at AA (years), mean (SEM) | 64.7 (2.3) | 62.1 (1.4) | ns |
| Age at disease onset (years), mean (SEM) | 47.0 (4.7) | 36.9 (5.2) | ns |
| Treatment V1 to last visit (years), mean (SEM) | 4.9 (0.7) | 3.8 (0.6) | ns |
| Primary disease, n (%) | |||
| Arthritis | 9 (26.5) | 9 (36.0) | ns |
| IBD | 5 (14.7) | 3 (12.0) | |
| Other | 4 (11.8) | 4 (16.0) | |
| Idiopathic | 16 (47.1) | 9 (36.0) | |
| Concomitant disease, n (%) | ns | ||
| Arterial hypertension | 13 (38.2) | 9 (36.0) | |
| Diabetes mellitus type 2 | 1 (2.9) | 1 (4.0) | |
| Metabolic syndrome | 2 (5.9) | 2 (8.0) | |
| None | 18 (52.9) | 13 (52.0) | |
| Serum creatinine at V1 (mg/dL), n (%) | |||
| <2.5 | 20 (58.8) | 14 (56.0) | ns |
| 2.5–5 | 11 (32.4) | 7 (28.0) | ns |
| ESRD at V1, n (%) | 3 (8.8) | 4 (16.0) | ns |
| Serum creatinine at last visit (mg/dL), n (%) | |||
| <2.5 | 24 (70.6) | 7 (28.0) | 0.002 |
| 2.5–5 | 3 (8.8) | 2 (8.0) | ns |
| ESRD at last visit, n (%) | 7 (20.6) | 16 (64.0) | 0.001 |
| Protein to creatinine ratio at V1 (g/mol), n (%) | |||
| <300 | 14 (41.2) | 7 (28.0) | ns |
| 300–1000 | 7 (20.6) | 8 (32.0) | ns |
| >1000 | 13 (38.2) | 10 (40.0) | ns |
| Protein to creatinine ratio at last visit (g/mol), n (%) | |||
| <300 | 14 (41.2) | 3 (12.0) | 0.020 |
| 300–1000 | 3 (8.8) | 4 (16.0) | ns |
| >1000 | 17 (50.0) | 18 (72.0) | ns |
| CRP at V1, mean (SEM) | 33.9 (3.7) | 36.5 (2.2) | ns |
| CRP at last visit (<5 mg/L) | 5.5 (0.9) | 15.9 (1.3) | 0.045 |
| P value V1 vs last visit | 0.01 | 0.045 | |
| SAA at V1, mean (SEM) | 63.1 (4.6) | 30.0 (3.4) | ns |
| SAA at last visit (<8.6 mg/L) | 12.1 (1.8) | 7.4 (0.8) | ns |
| P value V1 vs last visit | 0.01 | 0.045 | |
| BMI (kg/m2), mean (SEM) | 30.74 (1.32) | 28.82 (1.48) | ns |
| SAA1α/α, n (%) | 23 (95.8) | 18 (93.3) | ns |
AA, AA amyloidosis; bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; cid+AA, patients with chronic inflammatory diseases and AA amyloidosis; CRP, C reactive protein; ESRD, end-stage renal disease; IBD, inflammatory bowel disease; idio+AA, patients with idiopathic AA amyloidosis; SAA, serum amyloid alpha; V1, visit 1.